Lenalidomide Newbury (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4‑E3 ubiquitin ligase complex, causing selective degradation of transcription factors Ikaros and Aiolos. This action reduces pro‑inflammatory cytokine production, enhances the activity of T‑cells and natural killer cells, and blocks new blood‑vessel formation, together producing an anti‑cancer effect.

The dosage of Lenalidomide Newbury is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment history. Only a qualified healthcare professional can determine the appropriate dose and schedule for each patient.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception. The drug is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the Lenalidomide Newbury product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class, similar to thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally has a more favorable side‑effect profile, especially lower rates of peripheral neuropathy, while offering comparable anti‑myeloma activity. Pomalidomide is a newer IMiD used after lenalidomide failure, offering potency but with a different safety spectrum.

Lenalidomide Newbury should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain stability.

The medication is taken orally, usually once daily, with or without food. Tablets should be swallowed whole with a full glass of water and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to infections, hepatotoxicity indicated by elevated liver enzymes, and the rare possibility of secondary malignancies. Patients should report any signs of clotting, fever, unexplained bruising, or liver‑related symptoms promptly.

Lenalidomide should not be used by pregnant women or women who could become pregnant without effective contraception. It is also contraindicated in patients with severe renal impairment unless dose adjustments are made, and in individuals with a known hypersensitivity to lenalidomide or any of its excipients.